{
    "pmcid": "8782626",
    "qa_pairs": {
        "What method was used to map the binding sites of the antibodies on the receptor-binding domain?": [
            "Hydrogen-deuterium exchange coupled with mass spectrometry (HDX-MS)",
            "X-ray crystallography",
            "Cryo-electron microscopy",
            "Nuclear magnetic resonance (NMR) spectroscopy"
        ],
        "What technology was used to isolate mouse monoclonal antibodies targeting the receptor-binding domain of the Spike protein?": [
            "Hybridoma technology",
            "Phage display technology",
            "CRISPR-Cas9 technology",
            "Yeast surface display technology"
        ],
        "What was the result of prophylactic administration of the antibodies in an ACE2-humanized mouse model?": [
            "Reduced viral burden and inflammation in the lungs, preventing disease progression",
            "Increased viral load and inflammation in the lungs, exacerbating disease progression",
            "No change in viral burden or inflammation in the lungs",
            "Complete eradication of the virus from the bloodstream"
        ],
        "Which two monoclonal antibodies were identified as having high neutralizing potency against SARS-CoV-2 and its variants?": [
            "AX290 and AX677",
            "AX123 and AX456",
            "AX789 and AX890",
            "AX101 and AX202"
        ],
        "Which variant's Spike protein did AX677 show binding to, suggesting its potential efficacy against this variant?": [
            "Omicron variant",
            "Lambda variant",
            "Mu variant",
            "Gamma variant"
        ]
    }
}